Abstract
We have genotyped 1101 supposedly healthy subjects from the Stanislas cohort for the lipoprotein lipase (LPL) gene Ser417(C)-->stop (G) polymorphism and/or for the apolipoprotein (apo)E common polymorphism. Genotypic effects of the two polymorphisms on fasting serum triglycerides (TG), total cholesterol (Tchol), high density lipoprotein-cholesterol (HDLc), low density lipoprotein-cholesterol (LDLc), apoB, apoA-I, and apoE levels were studied separately for each polymorphism and in conjunction. epsilon 4 allele and high apoE levels were associated with high levels of LDLc, Tchol, apoB, and TG. The G allele of LPL was significantly associated with low TG levels. We found a clear interaction between the LPL/apoE polymorphisms and apoE levels on serum TG variation. Total variability of TG levels in women and men of 42.31% and 53.62% respectively, were mainly explained by apoE concentration and these two polymorphisms. ApoE and LPL genes simultaneously modulated TG levels.
Highlights
Gene Ser447(C+) stop (G) polymorphism and/or for the apolipoproteinE common polymorphism
Synthesized and secreted into the circulation by many tissues. It is bound in its active homodimeric form via glycosaminoglycans to the luminal surface of capillary endothelial cells [7].lipoprotein lipase (LPL) plays a key role in lipoprotein metabolism, both as an enzyme that hydrolyzes triglycerides of very low density lipoproteins (VLDL) and chylomicrons [8],and as a mediator for lipoprotein interaction with cell surfaces and receptors [9,10,11,12,13,14,15,16,17]
We examined 1) the impact of the Apolipoprotein E (apoE) polymorphism and the (C/ G)LPL447polymorphism on lipid levels independently; 2) the combined influence of the apoE common polymorphism and the (C/G)LPL447polymorphism on lipid levels; and 3) the interaction between these gene polymorphisms, apoE levels, and other factors (BMI,WHR, oral contraceptive (OC) use, gender, age, consumption of alcohol), concerning their influence on lipid traits
Summary
Men and women from the STANISLAS cohort [31], who underwent a routine health examination at the Center for Preventive Medicine in Nancy, France, were included in this study. These individuals (1101 total) were selected following the exclusion criteria which were the use of hypolipidemic medication and abnormal liver metabolism as defined by elevated activities of alanine aminotransferase (ALAT> 130U/1), aspartate aminotransferase (ASAT > 90 U/l), or gamma-glutamyltransferase (GGT > 150 U/l). Subjects with TG levels higher than 6 mmol/l were alsoexcluded from the study
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
